G蛋白偶联受体
受体
双分子荧光互补
趋化因子受体
癌细胞
CXCR4型
化学
癌症
蛋白质-蛋白质相互作用
细胞生物学
生物
生物化学
趋化因子
遗传学
酵母
作者
Junyi Liang,Mohamed Seghiri,Pradeep Kumar Singh,Hyeon Gyu Seo,J Lee,Yoonjung Jo,Yong Bhum Song,Chulo Park,P. Zalicki,Jae-Yeon Jeong,Won‐Ki Huh,Niña G. Caculitan,Adam W. Smith
标识
DOI:10.1073/pnas.2304897121
摘要
While the existence and functional role of class C G-protein-coupled receptors (GPCR) dimers is well established, there is still a lack of consensus regarding class A and B GPCR multimerization. This lack of consensus is largely due to the inherent challenges of demonstrating the presence of multimeric receptor complexes in a physiologically relevant cellular context. The C-X-C motif chemokine receptor 4 (CXCR4) is a class A GPCR that is a promising target of anticancer therapy. Here, we investigated the potential of CXCR4 to form multimeric complexes with other GPCRs and characterized the relative size of the complexes in a live-cell environment. Using a bimolecular fluorescence complementation (BiFC) assay, we identified the β2 adrenergic receptor (β2AR) as an interaction partner. To investigate the molecular scale details of CXCR4-β2AR interactions, we used a time-resolved fluorescence spectroscopy method called pulsed-interleaved excitation fluorescence cross-correlation spectroscopy (PIE-FCCS). PIE-FCCS can resolve membrane protein density, diffusion, and multimerization state in live cells at physiological expression levels. We probed CXCR4 and β2AR homo- and heteromultimerization in model cell lines and found that CXCR4 assembles into multimeric complexes larger than dimers in MDA-MB-231 human breast cancer cells and in HCC4006 human lung cancer cells. We also found that β2AR associates with CXCR4 multimers in MDA-MB-231 and HCC4006 cells to a higher degree than in COS-7 and CHO cells and in a ligand-dependent manner. These results suggest that CXCR4-β2AR heteromers are present in human cancer cells and that GPCR multimerization is significantly affected by the plasma membrane environment.
科研通智能强力驱动
Strongly Powered by AbleSci AI